

6-17-04

File 1636

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV457202598US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: June 16, 2004

Signature:

(Richard Zimmermann)



Packet No.: 28335/36996US
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Jeffrey S. Bartlett

Confirmation No.:

Application No.: 10/038,972

Art Unit: 1636

Filed: January 4, 2002

Examiner: M. Marvich

For: AAV2 VECTORS AND METHODS

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The Applicants request that the documents listed on the attached Form PTO-1449 be made of official record in the above-identified application and considered by the Examiner during examination of the above-identified patent application. Copies of all documents (B1 and C1-C21) are submitted herewith.

This Information Disclosure Statement is not intended to be an admission that a search has been made, that other relevant art does not exist, or that any of the information disclosed herein constitutes prior art under 35 U.S.C. §102 or §103.

06/18/2004 JADD01 00000101 10038972

01 FC:1806

180.00 OP


Application No.: 10/038,972

Docket No.: 28335/36996US

This Information Disclosure Statement is filed after receipt of a first Office Action on the merits. Submitted herewith is our check (\$180.00) for payment of the fee according to 37 C.F.R. §1.97(b)(3). Please charge any additional fees due in connection with this Information Disclosure Statement to Deposit Account No. 13-2855.

Dated: June 16, 2004

Respectfully submitted,

By: 
Sharon M. Sinnich

Registration No.: 48,484

MARSHALL, GERSTEIN & BORUN LLP

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Agent for Applicant

Form PTO-1449 (Modified)

Atty. Docket No.

28335/36996US

Serial No.

10/038,972

INFORMATION DISCLOSURE STATEMENT

Applicant(s)


Jeffrey S. Bartlett

Filing Date

January 4, 2003

Art Unit

1636



U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Issue or Publication Date	Name	Class	Subclass	Filing Date (If Appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Publication Date	Country	Translation	
				Yes	No
B1	WO00/28004	05/18/2000	PCT		

OTHER DOCUMENTS

C1	Srivastava, <i>et al.</i> , Nucleotide Sequence and Organization of the Adeno-Associated Virus 2 Genome, <i>Journal of Virology</i> 45 (2): 555-564 (February 1983).
C2	Ruffing <i>et al.</i> , Mutations in the carboxy terminus of adeno-associated virus 2 capsid proteins affect viral infectivity: lack of an RGD integrin-binding motif, <i>Journal of General Virology</i> 75: 3385-3392 (1994).
C3	Hermonat <i>et al.</i> , Genetics of Adeno-Associated Virus: Isolation and Preliminary Characterization of Adeno-Associated Virus Type 2 Mutants, <i>Journal of Virology</i> 51 (2): 329-339 (August 1984).
C4	Santiago <i>et al.</i> , New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury, <i>Nature Medicine</i> 5 (11): 1264-1269 (November 1999).
C5	Muzyczka, Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells, <i>Current Topics in Microbiology and Immunology</i> 158: 97-129 (1992).
C6	Girod <i>et al.</i> , Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2, <i>Nature Medicine</i> 5 (9): 1052-1056 (September 1999).
C7	Rabinowitz <i>et al.</i> , Insertional Mutagenesis of AAV2 Capsid and the Production of Recombinant Virus, <i>Virology</i> 265: 274-285 (1999).

EXAMINER:

DATE CONSIDERED:

Form PTO-1449 (Modified)



Atty. Docket No.

28335/36996US

Serial No.

10/038,972

Applicant(s)

Jeffrey S. Bartlett

Filing Date

January 4, 2003

Art Unit

1636

INFORMATION DISCLOSURE STATEMENT

C8	Tsao <i>et al.</i> , The Three-Dimensional Structure of Canine Parvovirus and Its Functional Implications, <i>Science</i> 251: 1456-1464 (March 1991).
C9	Wu <i>et al.</i> , The Canine Parvovirus Empty Capsid Structure, <i>J. Mol. Biol.</i> 233 (2): 231-244 (1993).
C10	Agbandje <i>et al.</i> , Structure Determination of Feline Panleukopenia Virus Empty Particles, <i>Proteins</i> 16: 155-171 (June 1993).
C11	Agbandje-McKenna <i>et al.</i> , Functional implications of the structure of the murine parvovirus, minute virus of mice, <i>Structure</i> 6 (11): 1369-1381 (November 1998).
C12	Llamas-Saiz <i>et al.</i> , Structure Determination of Minute Virus of Mice, <i>Acta Crystallographica Section D</i> D53: 93-102 (1997).
C13	Chipman <i>et al.</i> , Cryo-electron microscopy studies of empty capsids of human parvovirus B19 complexed with its cellular receptor, <i>Proc. Natl. Acad. Sci. USA</i> 93: 7502-7506 (July 1996).
C14	McKenna <i>et al.</i> , Three-Dimensional Structure of Aleutian Mink Disease Parvovirus: Implications for Disease Pathogenicity, <i>Journal of Virology</i> 73 (8): 6882-6891 (August 1999).
C15	Wu <i>et al.</i> , Mutational Analysis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Construction of AAV2 Vectors with Altered Tropism, <i>Journal of Virology</i> 74 (18): 8635-8647 (September 2000).
C16	Shi <i>et al.</i> , Insertional Mutagenesis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Generation of AAV2 Vectors Targeted to Alternative Cell-Surface Receptors, <i>Human Gene Therapy</i> , 12: 1697-1711 (September 2001).
C17	Bartlett <i>et al.</i> , Infectious Entry Pathway of Adeno-Associated Virus and Adeno-Associated Virus Vectors. <i>Journal of Virology</i> , 74(6): 2777-2785 (1999).
C18	Kigawa <i>et al.</i> , Adenovirus-mediated Transfer of a p53 Gene in Ovarian Cancer, <i>Adv. Exp. Med. Biol.</i> 465(14): 207-14 (2000).
C19	Song <i>et al.</i> , In vivo Studies of Adenovirus-mediated p53 Gene Therapy for Cis-platinum-Resistant Human Ovarian Tumor Xenografts, <i>Oncol. Res.</i> , 11(3): 153-159m (1999).
C20	Yamaguchi <i>et al.</i> , Co-transfection of Herpes Simplex Virus Thymidine Kinase Gene and Human Interleukin-2 Gene into Mouse Ovarian Cancer Cell Line, OVHM, <i>Intl. J. Mol. Med.</i> , 6(2): 185-190 (2000).
C21	Genbank Accession No. AF043303, Adeno-Associated Virus 2 (February 24, 1998)

EXAMINER:

DATE CONSIDERED: